United Therapeutics (NASDAQ:UTHR) Director Jan Malcolm Sells 325 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 325 shares of United Therapeutics stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the sale, the director owned 450 shares in the company, valued at $247,765.50. This represents a 41.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Down 1.0%

Shares of United Therapeutics stock traded down $5.42 on Friday, hitting $547.06. 301,306 shares of the company’s stock traded hands, compared to its average volume of 492,988. The stock has a market cap of $23.22 billion, a P/E ratio of 20.19, a PEG ratio of 1.82 and a beta of 0.58. The firm’s 50-day moving average is $557.18 and its 200 day moving average is $529.32. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the business posted $6.63 EPS. Equities research analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC increased its position in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP boosted its stake in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC increased its stake in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Finally, Darwin Global Management Ltd. acquired a new stake in United Therapeutics during the 3rd quarter valued at $317,617,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of several research analyst reports. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. HC Wainwright lifted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Raymond James Financial began coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada lifted their target price on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research report on Tuesday. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $644.82.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.